Figure 4

Range of plausible projections: expenditures under extreme case scenarios, 2001–2012. a, b: "High Extreme" Case; c, d: Base Case modified "LisDEX without clinical advantage over MPH-MR"; e, f: "Low Extreme" Case; left: England; right: Germany. MPH: methylphenidate; IR: immediate-release formulations (Ritalin^R, branded generics [Equasym^R, Medikinet^R], generics; Focalin^R); MR: modified-release formulations (Concerta^R XL, Equasym^R XL, Medikinet^R retard, Focalin^R XR; MPH-Patch: transdermal system (Daytrana^R); LisDEX: lisdexamphetamine (NRP104); Nonstimulants: ATX, atomoxetine (Strattera^R), ARM, armodafinil (Sparlon^R); DEX: dexamphetamine (England only).